医学
溶血
入射(几何)
输血
血液学
外围设备
内科学
麻醉
外周血
外科
输血医学
导管
显著性差异
全血
统计分析
临床试验
并发症
年轻人
作者
Dong Fan,Yin Jiang,Zhu Meng,Jinyan Han,Weifeng Li,Qiuyue Liu,Yanyan Zhang,Juan Zhao
标识
DOI:10.1177/11297298261435068
摘要
Objective: To evaluate the safety and efficacy of 26-gauge short peripheral catheters (SPCs) for blood transfusion in adults with hematological diseases. Study design and methods: This integrated study combined in vitro experiments with a historical clinical control. In vitro assessments evaluated mechanical hemolysis and transfusion duration for four blood components. Clinically, hematology patients from October 2022 to September 2023 served as controls ( n = 300), while those from October 2023 to September 2024 comprised the observation group ( n = 300). Outcomes included hemolytic symptoms and signs, transfusion duration, first-attempt success, pain scores, and catheter-related complications. Statistical analysis employed t -tests, chi-square tests, and Mann-Whitney U tests. Results: In vitro experiments demonstrated no mechanical hemolysis, with all components transfused within standard requirements. Clinically, no hemolysis occurred, with all components transfused within specified timeframes. The observation group demonstrated significantly higher first-attempt success (91.33% vs 84.33%), lower pain scores (1.64 ± 0.70 vs 2.49 ± 0.84), and reduced phlebitis incidence (9.67% vs 19.00%; all p < .05). No significant differences were observed in catheter blockage, bleeding incidence, or indwelling duration between groups. Conclusion: Using 26-gauge SPCs for transfusion caused no mechanical hemolysis, met transfusion duration requirements, and resulted in higher first-attempt success, reduced pain, and lower phlebitis incidence. Therefore, they are recommended for adult patients with hematological diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI